Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2017

View Archived Issues

Daiichi Sankyo announces pipeline highlights of second quarter of fiscal 2017

Arvinas selects clinical candidate for metastatic castration-resistant prostate cancer

Astellas profiles pipeline progress of second quarter of fiscal 2017

FPT-155: a novel therapeutic CD80-Fc fusion protein with potent antitumor activity in vivo

Clinical evaluation of 177Lu-PP-F11N underway in medullary thyroid cancer

FDA clears IND for GALGT2 gene therapy program for DMD

Jazz Pharmaceuticals submits MAA for Vyxeos as treatment of high-risk AML

Ionis Pharmaceuticals submits MAA to the EMA for inotersen

Alios BioPharma moves potent and selective TLR7 agonist AL-034 into the clinic

Sanofi describes novel glucagon receptor ligands for diabetes drug development

Boehringer Ingelheim patents OX1 receptor antagonists

Pfizer reflects on achievements of third quarter 2017

Ono Pharmaceutical divulges novel voltage-gated channel activators

AstraZeneca identifies ERalpha antagonists and SERDs

McGill University discloses ARK-1 and PKC-alpha inhibitors

KRICT presents NAE1 and SAE inhibitors for cancer

Novartis submits MAA for tisagenlecleucel for B-cell ALL and DLBCL

Biohaven initiates bioequivalence study of BHV-0223 ODT formulation of riluzole

Procalcitonin levels have prognostic significance in patients with acute liver failure

Moderna Therapeutics, AstraZeneca to develop AZD-7970 for heart failure

ADCendo signs license agreement to support development of cancer drugs

Inovio Pharmaceuticals begins phase Ib/IIa immuno-oncology trial in glioblastoma

iPharma and Boehringer Ingelheim enter license agreement for BI-853520

FDA approves oral Vimpat for partial-onset seizures in pediatric patients

Bayer seeks E.U. approval of rivaroxaban for patients with coronary or peripheral artery disease

FDA lifts clinical hold on phase Ib trial of PTX-200 in ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...